

PROGRAM



8.00am	Registration - Tea, coffee and light refreshments provided
8.30am	Introduction and Acknowledgement of Country Dr Claudia Rutherford and Associate Professor Anthony Joshua Co-Chairs, Sydney Catalyst International Translational Cancer Research Symposium 2019
8.40am	Welcome - Professor Michael Boyer, Director of Sydney Catalyst
8.45am	The future of cancer research in New South Wales - Dr Veronica McCabe Director Strategic Research Investment, Cancer Institute NSW

SESSION 1: BENCH TO BEDSIDE

CHAired BY ASSOCIATE PROFESSOR ANTHONY JOSHUA

9.00am	Professor Margaret Tempero <i>The University of California, San Francisco, USA</i> Dissecting Biology: Finding new therapeutic targets in pancreatic adenocarcinoma
9.40am	01 Professor John Simes <i>Sydney Catalyst, NHMRC Clinical Trials Centre, The University of Sydney</i> Embedding Research (and Evidence) in Cancer Healthcare: an update on the Sydney Catalyst EnRICH Program
9.55am	02 Dr Liz Caldon <i>The Garvan Institute of Medical Research</i> BRCA1 mutation stabilises cyclin E1 in breast cancer to create a therapeutically targetable subset
10.10am	03 Dr Helen McGuire <i>Ramaciotti Facility for Human Systems Biology, The University of Sydney</i> Predictive immune signature analysis for cancer application
10.25am	RAPID FIRE PRESENTATIONS (3 mins)
Rapid Fire	04 Dr Ashleigh Parkin <i>The Garvan Institute of Medical Research</i> Dual inhibition of JAK and Src: A novel and synergistic combination to target pancreatic tumours and their microenvironment
Rapid Fire	05 Dr Emma Ramsay <i>Sydney Catalyst, NHMRC Clinical Trials Centre, The University of Sydney</i> Procoagulant platelets as a diagnostic predictor of thrombosis in lung cancer patients
Rapid Fire	06 Dr Holly Holliday <i>The Garvan Institute of Medical Research</i> MicroRNA-based therapeutics for the treatment of high risk neuroblastoma
Rapid Fire	07 Hansol Lee <i>Melanoma Institute Australia</i> Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy

10.40am	MORNING TEA + POSTER VIEWING	
SESSION 2: EVIDENCE IN PRACTICE RESEARCH		CHAired BY DR CLAUDIA RUTHERFORD
11.10am	<p>Professor Galina Velikova <i>The University of Leeds, UK</i> The increasing role of Patient Reported Outcomes in cancer care: From clinical trials to patient support and care quality measure</p>	
11.50am	08	<p>Dr Diana Naehrig <i>Chris O'Brien Lifehouse</i> Patient reported outcomes and treatment uptake of Integrative Oncology and Supportive Care Services at a tertiary cancer centre</p>
12.05pm	09	<p>Professor Phyllis Butow <i>Psycho-Oncology Cooperative Research Group, The University of Sydney</i> Molecular tumour profiling and whole genome sequencing: Psychosocial, ethical and behavioural issues</p>
12.20pm	10	<p>Hannah Timmins <i>Brain & Mind Centre, The University of Sydney</i> Understanding the relationship between patient experience and objective assessment of CIPN</p>
12.35pm	RAPID FIRE PRESENTATIONS (3 mins)	
Rapid Fire	11	<p>Nicci Bartley <i>Psycho-Oncology Cooperative Research Group, The University of Sydney</i> Cancer patients' views and understanding of genome sequencing: A qualitative study</p>
Rapid Fire	12	<p>Associate Professor Heather McKenzie <i>Cancer Nursing Research Unit, The University of Sydney</i> Evaluating a shared care pathway to support chemotherapy outpatients</p>
Rapid Fire	13	<p>Dr Rachael Dodd <i>Wiser Healthcare, The University of Sydney</i> Implementing renewal of the Cervical Screening Program in Australia: Health professionals' views and experiences</p>
Rapid Fire	14	<p>Dr Rachel Campbell <i>School of Psychology, The University of Sydney</i> Implementing patient-reported outcome measures (PROMs) in clinical practice: A meta-review of reviews</p>
12.50pm	LUNCH + POSTER VIEWING	

SESSION 3: CLINICAL RESEARCH

CHAired BY PROFESSOR DEREK RAGHAVAN

1.50pm	Professor Ian Harris <i>The University of Sydney and University of New South Wales</i> Raising the bar for surgical evidence	
2.30pm	15	Dr Daniel Steffens <i>Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital</i> Feasibility and acceptability of pre-operative exercise to improve patient outcomes after major cancer surgery
2.45pm	16	Dr Sathira Perera <i>Ingham Institute for Applied Medical Research, The University of New South Wales</i> Evidence based predictions for the demand for cancer surgery in Australia
3.00pm	Anton Enus <i>SBS Journalist and Presenter</i> The road to recovery from bowel cancer	
	10 MINUTE BREAK	

PANEL DISCUSSION

CHAired BY PROFESSOR DEREK RAGHAVAN

3.25pm	PERSONALISED MEDICINE: IS IT LIVING UP TO THE HYPE? Panellists: <ul style="list-style-type: none"> • Professor Galina Velikova, The University of Leeds, UK • Professor Margaret Tempero, The University of California, San Francisco, USA • Professor Ian Harris, University of New South Wales and The University of Sydney • Dr Amy Prawira, The Kinghorn Cancer Centre 	
4.10pm	AWARDS AND WRAP UP	
4.20pm	NETWORKING DRINKS + POSTER VIEWING 4.30PM: Hosted Poster Viewing 5.00PM: Networking Drinks	
6.00pm	EVENT FINISH	

POSTERS

SARA ARDEKANI	Dual mode trigger for drug delivery: pH- and ultrasound-responsive carbon quantum dots: Lifetime and fluorescent cell imaging microscopy tracking
NICCI BARTLEY	A systematic review of patient uncertainty when undertaking cancer genomic testing
MEGAN BEST	Patient preferences for receiving genomic test results Who should access Germline Genome Sequencing? A mixed methods study of patient views Patient perspectives on molecular tumor profiling: "Why wouldn't you?"
BEA BROWN	Psychological distress in never, ex, current, and passive smokers diagnosed with lung cancer - analyses from the EnRICH Program Patterns of care in a prospective clinical cohort of patients with lung cancer - preliminary analyses from EnRICH
BIQI CHEN	Investigation of radiation-induced bystander effects on cancer cells using NMR metabolomics
MEGAN CRUMBAKER	Retrospective oncological assessment of genome-driven precision medicine for metastatic prostate cancer
CLAIRE DAVIES	Translational-ANZGOG (TR-ANZGOG): Where molecular research meets clinical trials
ABDULLAH EMRAN	PD-L2 and PD1 promoter hypermethylation is a prognostic factor in melanoma patients and associated with poorer overall survival
NICHOLAS HINDLEY	Real-time direct diaphragm tracking during lung cancer radiotherapy
JOE JABBOUR	Development & assessment of an integrated patient information, education and support program in head and neck cancer
PEEY SEI KOK	Validation of progression-free survival (PFS) as a surrogate endpoint in randomised trials of immune checkpoint inhibitors (ICI) for advanced solid cancers
LIONEL LECK	Overcoming Pgp-mediated drug-resistance by releasing lysosomal stored doxorubicin with lysosomal targeting agents, DpC and Dp44mT
SYER LIM	Targeting the androgen receptor using a new class of thiosemicarbazone anti-cancer agents to overcome development of resistance in prostate cancer
HUI-MING LIN	Plasma lipidomic profiling of prostate cancer reveals prognostic lipids
LUKE MARINOVICH	Guidelines on margins for breast conserving surgery: Scoping review of clinical and economic impact
SAMANTHA OAKES	MCL-1 antagonism is effective in sensitizing pancreatic adenocarcinoma to SFK inhibition

BROOKE PEREIRA	Proteomic profiling of human prostate cancer-associated fibroblasts (CAF) reveals LOXL2-dependent regulation of the tumour microenvironment
LINDA ROGERS	Cone beam CT imaging dose reduces in vitro survival when combined with therapeutic irradiation
TAHLIA SCHEINBERG	Evaluation of a mainstream model of genetic testing for men with prostate cancer – study schema
CHINDHU SHUNMUGA SUNDARAM	A systematic review of psychological distress measures for people diagnosed with head and neck cancer (HNC)
FATEN TOUT	The multi-faceted efficacy of novel thiosemicarbazone anti-cancer agents in the Treatment of estrogen receptor positive breast cancer
CINDY TSENG	Targeting BET proteins and Mcl-1 for the treatment of human melanoma
MEGAN UFFEN-SMITH	Why do patients pursue cancer genomic testing? A systematic review of motivation
BEKESHO WENDIMU	A novel therapeutic approach to inhibit the oncogenic cross-talk between pancreatic cancer cells and the surrounding stroma

